Drug-Induced Interstitial Lung Disease: A Systematic ReviewCitation formats

  • External authors:
  • Nicholas Weatherley
  • Andrew Swift
  • Christopher Johns
  • Alessandro Giollo
  • James Wild
  • John Waterton
  • Ian Bruce
  • Colm Leonard
  • Stephen Bianchi
  • Nazia Chaudhuri

Standard

Drug-Induced Interstitial Lung Disease: A Systematic Review. / Skeoch, Sarah; Weatherley, Nicholas; Swift, Andrew; Oldroyd, Alexander; Johns, Christopher; Hayton, Conal; Giollo, Alessandro; Wild, James; Waterton, John; Buch, Maya; Linton, Kim; Bruce, Ian; Leonard, Colm; Bianchi, Stephen; Chaudhuri, Nazia.

In: Journal of Clinical Medicine, Vol. 7, No. 10, 15.10.2018, p. 356.

Research output: Contribution to journalArticlepeer-review

Harvard

Skeoch, S, Weatherley, N, Swift, A, Oldroyd, A, Johns, C, Hayton, C, Giollo, A, Wild, J, Waterton, J, Buch, M, Linton, K, Bruce, I, Leonard, C, Bianchi, S & Chaudhuri, N 2018, 'Drug-Induced Interstitial Lung Disease: A Systematic Review', Journal of Clinical Medicine, vol. 7, no. 10, pp. 356. https://doi.org/10.3390/jcm7100356

APA

Skeoch, S., Weatherley, N., Swift, A., Oldroyd, A., Johns, C., Hayton, C., Giollo, A., Wild, J., Waterton, J., Buch, M., Linton, K., Bruce, I., Leonard, C., Bianchi, S., & Chaudhuri, N. (2018). Drug-Induced Interstitial Lung Disease: A Systematic Review. Journal of Clinical Medicine, 7(10), 356. https://doi.org/10.3390/jcm7100356

Vancouver

Skeoch S, Weatherley N, Swift A, Oldroyd A, Johns C, Hayton C et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. Journal of Clinical Medicine. 2018 Oct 15;7(10):356. https://doi.org/10.3390/jcm7100356

Author

Skeoch, Sarah ; Weatherley, Nicholas ; Swift, Andrew ; Oldroyd, Alexander ; Johns, Christopher ; Hayton, Conal ; Giollo, Alessandro ; Wild, James ; Waterton, John ; Buch, Maya ; Linton, Kim ; Bruce, Ian ; Leonard, Colm ; Bianchi, Stephen ; Chaudhuri, Nazia. / Drug-Induced Interstitial Lung Disease: A Systematic Review. In: Journal of Clinical Medicine. 2018 ; Vol. 7, No. 10. pp. 356.

Bibtex

@article{60c0701021b04090945062c34a709eff,
title = "Drug-Induced Interstitial Lung Disease: A Systematic Review",
abstract = "Background: Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous agents, but the risk often only becomes apparent after the marketing authorisation of such agents. Methods: In this PRISMA-compliant systematic review, we aimed to evaluate and synthesise the current literature on DIILD. Results: Following a quality assessment, 156 full-text papers describing more than 6000 DIILD cases were included in the review. However, the majority of the papers were of low or very low quality in relation to the review question (78%). Thus, it was not possible to perform a meta-analysis, and descriptive review was undertaken instead. DIILD incidence rates varied between 4.1 and 12.4 cases/million/year. DIILD accounted for 3–5% of prevalent ILD cases. Cancer drugs, followed by rheumatology drugs, amiodarone and antibiotics, were the most common causes of DIILD. The radiopathological phenotype of DIILD varied between and within agents, and no typical radiological pattern specific to DIILD was identified. Mortality rates of over 50% were reported in some studies. Severity at presentation was the most reliable predictor of mortality. Glucocorticoids (GCs) were commonly used to treat DIILD, but no prospective studies examined their effect on outcome. Conclusions: Overall high-quality evidence in DIILD is lacking, and the current review will inform larger prospective studies to investigate the diagnosis and management of DIILD",
author = "Sarah Skeoch and Nicholas Weatherley and Andrew Swift and Alexander Oldroyd and Christopher Johns and Conal Hayton and Alessandro Giollo and James Wild and John Waterton and Maya Buch and Kim Linton and Ian Bruce and Colm Leonard and Stephen Bianchi and Nazia Chaudhuri",
year = "2018",
month = oct,
day = "15",
doi = "10.3390/jcm7100356",
language = "English",
volume = "7",
pages = "356",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "MDPI",
number = "10",

}

RIS

TY - JOUR

T1 - Drug-Induced Interstitial Lung Disease: A Systematic Review

AU - Skeoch, Sarah

AU - Weatherley, Nicholas

AU - Swift, Andrew

AU - Oldroyd, Alexander

AU - Johns, Christopher

AU - Hayton, Conal

AU - Giollo, Alessandro

AU - Wild, James

AU - Waterton, John

AU - Buch, Maya

AU - Linton, Kim

AU - Bruce, Ian

AU - Leonard, Colm

AU - Bianchi, Stephen

AU - Chaudhuri, Nazia

PY - 2018/10/15

Y1 - 2018/10/15

N2 - Background: Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous agents, but the risk often only becomes apparent after the marketing authorisation of such agents. Methods: In this PRISMA-compliant systematic review, we aimed to evaluate and synthesise the current literature on DIILD. Results: Following a quality assessment, 156 full-text papers describing more than 6000 DIILD cases were included in the review. However, the majority of the papers were of low or very low quality in relation to the review question (78%). Thus, it was not possible to perform a meta-analysis, and descriptive review was undertaken instead. DIILD incidence rates varied between 4.1 and 12.4 cases/million/year. DIILD accounted for 3–5% of prevalent ILD cases. Cancer drugs, followed by rheumatology drugs, amiodarone and antibiotics, were the most common causes of DIILD. The radiopathological phenotype of DIILD varied between and within agents, and no typical radiological pattern specific to DIILD was identified. Mortality rates of over 50% were reported in some studies. Severity at presentation was the most reliable predictor of mortality. Glucocorticoids (GCs) were commonly used to treat DIILD, but no prospective studies examined their effect on outcome. Conclusions: Overall high-quality evidence in DIILD is lacking, and the current review will inform larger prospective studies to investigate the diagnosis and management of DIILD

AB - Background: Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous agents, but the risk often only becomes apparent after the marketing authorisation of such agents. Methods: In this PRISMA-compliant systematic review, we aimed to evaluate and synthesise the current literature on DIILD. Results: Following a quality assessment, 156 full-text papers describing more than 6000 DIILD cases were included in the review. However, the majority of the papers were of low or very low quality in relation to the review question (78%). Thus, it was not possible to perform a meta-analysis, and descriptive review was undertaken instead. DIILD incidence rates varied between 4.1 and 12.4 cases/million/year. DIILD accounted for 3–5% of prevalent ILD cases. Cancer drugs, followed by rheumatology drugs, amiodarone and antibiotics, were the most common causes of DIILD. The radiopathological phenotype of DIILD varied between and within agents, and no typical radiological pattern specific to DIILD was identified. Mortality rates of over 50% were reported in some studies. Severity at presentation was the most reliable predictor of mortality. Glucocorticoids (GCs) were commonly used to treat DIILD, but no prospective studies examined their effect on outcome. Conclusions: Overall high-quality evidence in DIILD is lacking, and the current review will inform larger prospective studies to investigate the diagnosis and management of DIILD

U2 - 10.3390/jcm7100356

DO - 10.3390/jcm7100356

M3 - Article

VL - 7

SP - 356

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 10

ER -